Healthcare system factors influencing treatment results of patients with multidrug-resistant tuberculosis
In 2012, 5% of the cases of TB for which drug susceptibility test results were available, were reported to be multidrug resistant (MDR). Treatment for MDR TB is lengthy, toxic, expensive, and has generally poor outcomes. Inadequate treatment can lead to unfavourable outcomes for the patient and also increases the risk of transmission and the development of resistance to even more drugs.
Qualitative research was therefore carried out in four EU countries to try to identify the factors of a healthcare system that are key to achieving good treatment results for patients with multidrug-resistant tuberculosis.
Review of reviews and guidelines on target groups, diagnosis, treatment and programmatic issues for implementation of latent tuberculosis management
15 Oct 2018 - This report is part of a series of technical documents describing the collection, synthesis and appraisal of the available information on specific measures for the prevention, identification and treatment of LTBI, analysed from the perspective of national TB-control programmes.
Systematic review on the prevention and control of blood-borne viruses in prison settings
23 Jul 2018 - The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, with a focus on the countries of the European Union (EU) and the European Economic Area (EEA).
Social determinants and risk factors in tuberculosis surveillance in the EU/EEA
24 May 2018 - The objective of this report is to provide countries with advice on what social determinant and risk factor variables to collect and what definitions to use, and to propose information to be collected at the national and European level.